NGNE today
$25.10-$0.18 (-0.71%)close Nov 11, 2026Trend
DailyUptrend (confirmed)
4 hourStrong Bullish
1 hourStrong Bearish
15 minSymmetric Triangle
5 minSymmetric Triangle
Daily trend turns down below $15.93
Key levels
Resistance$29.63
Resistance$26.94
Support$23.07
Support$19.13
Latest news & SEC filings
AnalystHC Wainwright keeps Buy rating on Neurogene, cuts price target to $60
EarningsNeurogene Posts Q3 2026 Results
SEC FilingNeurogene Inc. filed a report on a major company event (Form 8-K)
All NGNE news →About Neurogene
Neurogene is a clinical-stage biotechnology company working on treatments for uncommon disorders of the nervous system. Its most advanced candidate, NGN-401, is a gene therapy for Rett syndrome that relies on the company's EXACT technology to control how much therapeutic protein cells produce, and it is given by infusion into the brain's fluid-filled spaces. The company also pursues earlier-stage discovery work and makes its products at its own facility in Houston, Texas.
Based on the company's 10-K filed Mar 24, 2026.
Nasdaq · Healthcare
Neurogene Inc. (NGNE)
What Is the Price Target for NGNE?
SEPT Low Target
$60.00
SEPT Mid Target
$65.00
SEPT High Target
$166.00
Analyst Consensus
$65.00
Is NGNE a Buy or Sell Right Now?
Thesis
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for NGNE.
Start Free Trial →Is NGNE Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$54.66
12
Moat Score
NONE
1/9
Piotroski Score
12.0
Altman Z-Score
What Is Smart Money Doing with NGNE?
Insider Signal
SELLING
0 buys / 8 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →NGNE Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
0.93%
FCF Growth YoY
-9.7%
Revenue Trend
UNKNOWN
Dark Pool Trades for NGNE
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for NGNE, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:00:10 | $25.10 | 1,564 | $$39K | SELL |
| 21:00:10 | $25.10 | 1,000 | $$25K | SELL |
| 21:00:10 | $25.10 | 1,000 | $$25K | SELL |
| 20:23:37 | $25.33 | 2,580 | $$65K | SELL |
| 20:07:35 | $25.43 | 1,597 | $$41K | SELL |
5 dark pool trades shown · $$195K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Neurogene Inc. (NGNE) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →NGNE — frequently asked questions
What is NGNE stock price today?
Neurogene Inc. (NGNE) is at $25.10, down 0.71% (-$0.18) at the Nov 11, 2026 close.
Why is NGNE stock moving today?
Latest NGNE news — Nov 10, 2026: HC Wainwright keeps Buy rating on Neurogene, cuts price target to $60 · Nov 9, 2026: Neurogene Posts Q3 2026 Results
What is the NGNE price target?
The average analyst price target for NGNE is $65.00, ranging from $60 to $166, based on 5 analysts.
What do analysts rate NGNE?
Analyst ratings for NGNE: 1 Buy, 6 Hold, 0 Sell — consensus Hold.
Did NGNE beat earnings?
NGNE last reported on Aug 11, 2026: EPS -$1.53 vs -$1.42 expected — a miss of 7.7%.
Does NGNE pay a dividend?
NGNE does not currently pay a dividend.
What are NGNE support and resistance levels?
Support: $23.07, $19.13, $16.20. Resistance: $26.94, $29.63, $32.09.
What are insiders doing with NGNE?
Insider activity: SELLING, 0 buys and 8 sells in the last 90 days.
What is the latest news on NGNE?
Nov 10, 2026: HC Wainwright keeps Buy rating on Neurogene, cuts price target to $60 · Nov 9, 2026: Neurogene Posts Q3 2026 Results · Nov 9, 2026: Neurogene Inc. filed a report on a major company event (Form 8-K)